Axsome Therapeutics (AXSM) Current Assets (2015 - 2026)

Axsome Therapeutics' Current Assets history runs 12 years deep, the most recent figure standing at $611.2 million for Q1 2026.

• In Q1 2026, Current Assets rose 23.57% year-over-year to $611.2 million; the TTM figure through Mar 2026 stood at $611.2 million (up 23.57% YoY), while the FY2025 annual figure was $589.0 million, up 21.42% from the prior year.
• Current Assets came in at $611.2 million for Q1 2026 at Axsome Therapeutics, up from $589.0 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $611.2 million in Q1 2026 to a low of $86.8 million in Q1 2022.
• A 5-year average of $424.3 million and a median of $485.1 million in 2024 frame the typical range for Current Assets.
• Across the five-year window, Current Assets plunged 47.39% in 2022 and soared 399.81% in 2023, its largest moves.
• Axsome Therapeutics' Current Assets stood at $245.6 million in 2022, then jumped by 105.28% to $504.3 million in 2023, then fell by 3.81% to $485.1 million in 2024, then rose by 21.42% to $589.0 million in 2025, then grew by 3.77% to $611.2 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $611.2 million, $589.0 million, and $565.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison